Oral hormonal contraception should not be negated in BRCA1/BRCA2 mutation carriers not yet eligible for risk-reducing surgery because it significantly reduces the risk of developing ovarian cancer. The gene discussed is BRCA2; the disease is ovarian carcinoma.